Research Article

Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study

Table 2

Age-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for PCa in AAM and EAM and combined.

Rs# and gene; minor allele and its frequency Dominant model
OR (CI); P value
Recessive model
OR (CI); P value
Additive model
OR (CI); P value

rs4612601; EPHB2
AA: 0.49 (G)
EA: 0.45 (A)
AAM: 1.09 (0.63–1.9); 0.7490.86 (0.46–1.61); 0.6380.99 (0.69–1.41); 0.951
EAM: 1.18 (0.67–2.10); 0.5640.9 (0.52–1.56); 0.7091.02 (0.73–1.43); 0.912
All: 1.13 (0.76–1.69); 0.537 0.89 (0.59–1.34); 0.5651.00 (0.79–1.28); 0.969

rs4263970; EPHB2
AA: 0.47 (T)
EA: 0.45 (C)
AAM: 0.98 (0.57–1.68); 0.9320.88 (0.44–1.75); 0.7110.95 (0.66–1.38); 0.797
EAM: 1.08 (0.61–1.9); 0.7950.76 (0.44–1.33); 0.3340.93 (0.66–1.30); 0.665
All: 1.02 (0.69–1.5); 0.9180.81 (0.53–1.25); 0.3430.94 (0.73–1.21); 0.630

rs822396; ADIPOQ
AA: 0.2 (G)
EA: 0.15 (G)
AAM: 0.89 (0.52–1.52); 0.6711.64 (0.37–7.21); 0.5110.96 (0.6–1.54); 0.878
EAM: 0.75 (0.44–1.27); 0.2881.1 (0.29–4.09); 0.0940.82 (0.53–1.29); 0.392
All: 0.82 (0.56–1.19); 0.2851.29 (0.49–3.48); 0.6010.88 (0.64–1.22); 0.456

rs10993994; MSMB
AA: 0.2 (C)
EA: 0.34 (T)
AAM: 0.82 (0.48–1.4); 0.4721.04 (0.51–2.10); 0.9190.92 (0.63–1.33); 0.657
EAM: 1.04 (0.54–2.00); 0.8990.61 (0.36–1.05); 0.0770.81 (0.56–1.17); 0.258
All: 0.9 (0.6–1.35); 0.6110.75 (0.49–1.14); 0.1770.87 (0.67–1.11); 0.261

rs1859962; HNF1B
AA: 0.49 (G)
EA: 0.2 (G)
AAM: 1.03 (0.61–1.74); 0.9051.23 (0.54–2.81); 0.6261.06 (0.72–1.56); 0.752
EAM: 1.38 (0.77–2.45); 0.278 1.00 (0.57–1.76); 0.997 1.13 (0.79–1.6); 0.508
All: 1.16 (0.8–1.69); 0.4311.06 (0.67–1.69); 0.7901.09 (0.85–1.4); 0.503

rs7501939; HNF1B
AA: 0.48 (C)
EA: 0.49 (T)
AAM: 1.34 (0.73–2.47); 0.3432.42 (1.31–4.47); 0.00461.56 (1.08–2.27); 0.0193
EAM: 0.82 (0.5–1.35); 0.4391.13 (0.54–2.38); 0.7420.93 (0.65–1.33); 0.692
All: 0.99 (0.68–1.45); 0.9811.76 (1.11–2.79); 0.01671.18 (0.92–1.52); 0.187

rs4430796; HNF1B
AA: 0.34 (A)
EA: 0.47 (A)
AAM: 0.57 (0.34–0.97); 0.03830.64 (0.29–1.42); 0.2720.67 (0.46–0.99); 0.0431
EAM: 1.27 (0.7–2.3); 0.4390.98 (0.57–1.68); 0.9461.07 (0.76–1.51); 0.689
All: 0.81 (0.55–1.18); 0.2730.86 (0.59–1.33); 0.5000.87 (0.69–1.12); 0.279

rs2070874; IL4
AA: 0.45 (T)
EA: 0.2 (T)
AAM: 0.94 (0.54–1.64); 0.8241.45 (0.7–3.0); 0.3141.08 (0.73–1.59); 0.700
EAM: 0.65 (0.38–1.11); 0.1150.92 (0.22–3.93); 0.9160.72 (0.45–1.14); 0.161
All: 0.82 (0.57–1.17); 0.2751.32 (0.7–2.49); 0.3860.94 (0.71–1.24); 0.649

rs627839; RNASEL
AA: 0.46 (T)
EA: 0.45 (T)
AAM: 1.2 (0.7–2.06); 0.511 1.63 (0.78–3.42); 0.1921.24 (0.85–1.83); 0.252
EAM: 0.86 (0.5–1.47); 0.5710.99 (0.55–1.8); 0.9860.94 (0.67–1.32); 0.710
All: 1.01 (0.69–1.48); 0.9521.21 (0.76–1.91); 0.4271.06 (0.83–1.37); 0.632

rs4962416; CTBP2
AA: 0.23 (C)
EA: 0.23 (C)
AAM: 0.9 (0.5–1.59); 0.7095.65 (0.62–51.7); 0.1251.05 (0.63–1.74); 0.861
EAM: 1.69 (1.02–2.8); 0.04151.72 (0.68–4.31); 0.2511.52 (1.02–2.26); 0.0384
All: 1.28 (0.88–1.85); 0.1982.12 (0.92–4.9); 0.07841.31 (0.97–1.78); 0.083

Bolded values denote statistically significant associations.